Literature DB >> 35247927

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.

Jiannong Li1, Inna Smalley2, Zhihua Chen1, Jheng-Yu Wu2, Manali S Phadke2, Jamie K Teer1, Thanh Nguyen1, Florian A Karreth3, John M Koomen3, Amod A Sarnaik4, Jonathan S Zager4, Nikhil I Khushalani4, Ahmad A Tarhini4, Vernon K Sondak4, Paulo C Rodriguez5, Jane L Messina5, Y Ann Chen1, Keiran S M Smalley2,4.   

Abstract

PURPOSE: Acral melanoma is a rare subtype of melanoma that arises on the non-hair-bearing skin of the palms, soles, and nail beds. In this study, we used single-cell RNA sequencing (scRNA-seq) to map the transcriptional landscape of acral melanoma and identify novel immunotherapeutic targets. EXPERIMENTAL
DESIGN: We performed scRNA-seq on nine clinical specimens (five primary, four metastases) of acral melanoma. Detailed cell type curation was performed, the immune landscapes were mapped, and key results were validated by analysis of The Cancer Genome Atlas (TCGA) and single-cell datasets. Cell-cell interactions were inferred and compared with those in nonacral cutaneous melanoma.
RESULTS: Multiple phenotypic subsets of T cells, natural killer (NK) cells, B cells, macrophages, and dendritic cells with varying levels of activation/exhaustion were identified. A comparison between primary and metastatic acral melanoma identified gene signatures associated with changes in immune responses and metabolism. Acral melanoma was characterized by a lower overall immune infiltrate, fewer effector CD8 T cells and NK cells, and a near-complete absence of γδ T cells compared with nonacral cutaneous melanomas. Immune cells associated with acral melanoma exhibited expression of multiple checkpoints including PD-1, LAG-3, CTLA-4, V-domain immunoglobin suppressor of T cell activation (VISTA), TIGIT, and the Adenosine A2A receptor (ADORA2). VISTA was expressed in 58.3% of myeloid cells and TIGIT was expressed in 22.3% of T/NK cells.
CONCLUSIONS: Acral melanoma has a suppressed immune environment compared with that of cutaneous melanoma from nonacral skin. Expression of multiple, therapeutically tractable immune checkpoints were observed, offering new options for clinical translation. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35247927      PMCID: PMC9106889          DOI: 10.1158/1078-0432.CCR-21-3145

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  67 in total

Review 1.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

2.  Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.

Authors:  Hansol Lee; Camelia Quek; Ines Silva; Annie Tasker; Marcel Batten; Helen Rizos; Su Yin Lim; Tuba Nur Gide; Ping Shang; Grace H Attrill; Jason Madore; Jarem Edwards; Matteo S Carlino; Alexander Guminski; Robyn P M Saw; John F Thompson; Peter M Ferguson; Umaimainthan Palendira; Alexander M Menzies; Georgina V Long; Richard A Scolyer; James S Wilmott
Journal:  Oncoimmunology       Date:  2018-10-31       Impact factor: 8.110

3.  Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations.

Authors:  Patrik Theodor Nerdal; Christian Peters; Hans-Heinrich Oberg; Hristo Zlatev; Marcus Lettau; Elgar Susanne Quabius; Sofia Sousa; Daniel Gonnermann; Seppo Auriola; Daniel Olive; Jorma Määttä; Ottmar Janssen; Dieter Kabelitz
Journal:  J Immunol       Date:  2016-09-12       Impact factor: 5.422

Review 4.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

Review 5.  CD73-adenosine: a next-generation target in immuno-oncology.

Authors:  David Allard; Bertrand Allard; Pierre-Olivier Gaudreau; Pavel Chrobak; John Stagg
Journal:  Immunotherapy       Date:  2016-01-25       Impact factor: 4.196

6.  Integrating single-cell transcriptomic data across different conditions, technologies, and species.

Authors:  Andrew Butler; Paul Hoffman; Peter Smibert; Efthymia Papalexi; Rahul Satija
Journal:  Nat Biotechnol       Date:  2018-04-02       Impact factor: 54.908

7.  Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.

Authors:  M J Maeurer; S M Gollin; W J Storkus; W Swaney; J Karbach; D Martin; C Castelli; R Salter; A Knuth; M T Lotze
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

8.  Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Authors:  Lawrence Fong; Andrew Hotson; John D Powderly; Mario Sznol; Rebecca S Heist; Toni K Choueiri; Saby George; Brett G M Hughes; Matthew D Hellmann; Dale R Shepard; Brian I Rini; Shivaani Kummar; Amy M Weise; Matthew J Riese; Ben Markman; Leisha A Emens; Daruka Mahadevan; Jason J Luke; Ginna Laport; Joshua D Brody; Leonel Hernandez-Aya; Philip Bonomi; Jonathan W Goldman; Lyudmyla Berim; Daniel J Renouf; Rachel A Goodwin; Brian Munneke; Po Y Ho; Jessica Hsieh; Ian McCaffery; Long Kwei; Stephen B Willingham; Richard A Miller
Journal:  Cancer Discov       Date:  2019-11-15       Impact factor: 38.272

9.  Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.

Authors:  Inna Smalley; Eunjung Kim; Jiannong Li; Paige Spence; Clayton J Wyatt; Zeynep Eroglu; Vernon K Sondak; Jane L Messina; Nalan Akgul Babacan; Silvya Stuchi Maria-Engler; Lesley De Armas; Sion L Williams; Robert A Gatenby; Y Ann Chen; Alexander R A Anderson; Keiran S M Smalley
Journal:  EBioMedicine       Date:  2019-10-05       Impact factor: 8.143

10.  TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination.

Authors:  Gaia Cantelli; Jose L Orgaz; Irene Rodriguez-Hernandez; Panagiotis Karagiannis; Oscar Maiques; Xavier Matias-Guiu; Frank O Nestle; Rosa M Marti; Sophia N Karagiannis; Victoria Sanz-Moreno
Journal:  Curr Biol       Date:  2015-10-29       Impact factor: 10.834

View more
  4 in total

Review 1.  Research Progress of Cell Lineage Tracing and Single-Cell Sequencing Technology in Malignant Skin Tumors.

Authors:  Ang Li; Baoyi Liu; Jingkai Xu; Yong Cui
Journal:  Front Surg       Date:  2022-06-16

Review 2.  Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.

Authors:  Jianping Gui; Zhen Guo; Di Wu
Journal:  J Transl Med       Date:  2022-08-16       Impact factor: 8.440

3.  Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments.

Authors:  Zan He; Zijuan Xin; Qiong Yang; Chen Wang; Meng Li; Wei Rao; Zhimin Du; Jia Bai; Zixuan Guo; Xiuyan Ruan; Zhaojun Zhang; Xiangdong Fang; Hua Zhao
Journal:  Elife       Date:  2022-07-27       Impact factor: 8.713

Review 4.  Advanced Acral Melanoma Therapies: Current Status and Future Directions.

Authors:  Yiqun Zhang; Shijie Lan; Di Wu
Journal:  Curr Treat Options Oncol       Date:  2022-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.